Cytek Biosciences vs Cryoport
Cytek Biosciences and Cryoport are similar in size: $201m and $176m of revenue in their latest fiscal years. Cryoport grew faster (12.4% against 0.5%). Cryoport kept more of each dollar of sales as profit: a net margin of 44.4% against -33.0%. Cytek Biosciences carries less debt relative to equity (0.2% against 37.1%).
| Latest fiscal year | Cytek BiosciencesCTKB, 2025 | CryoportCYRX, 2025 |
|---|---|---|
| Revenue | $201m | $176m |
| Revenue growth | 0.5% | 12.4% |
| Net income | −$66.5m | $78.3m |
| Operating margin | -20.0% | -20.9% |
| Net margin | -33.0% | 44.4% |
| Return on equity | -18.0% | 17.3% |
| Free cash flow | −$8.8m | −$25.0m |
| Cash | $90.9m | $250m |
| Total debt | $525,000 | $186m |
| Debt to equity | 0.2% | 37.1% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | $15.1m | $10.0m |
| Employees | 702 | 738 |
| Market value | $774m | $844m |
| Price vs our value range | — | — |
| Moat score | 36 (Weak) | 19 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 14 sales |